Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARTRIDGE first-in-human BI 765128 trial in diabetic macular ischemia
NL-OMON53613Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2023
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BI 765128 in ischemic maculopathy (DMI) and diabetic retinopathy (DR) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of subjects with ocular dose limiting events and Number of subjects with drug-related adverse events. Started Feb 2023; status: completed.
02
Drugs
BI 765128
03
Conditions
ischemic maculopathy (DMI)diabetic retinopathy (DR)
Beyond the preview
Go deeper on NL-OMON53613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53613.